Patent Law Weblog
recent posts
- Apple v. Squires: USPTO Director Has Unlimited Discretion on IPR Institution
- The Ghost in the Machine: Why GenAI Can Be Both a Brilliant Researcher and a Terrible Advocate
- Bayer Files Suit Against Trio of COVID-19 Vaccine Makers
- Allen v. Cooper (4th Cir. 2026)
- To Require an Inventor ID, or Not to Require an Inventor ID – That Is the Question
about
Month: May 2009
-
By Mark Chael — On May 5th, Immunomedics, Inc. announced that its majority-owned subsidiary, IBC Pharmaceuticals, Inc., was granted U.S. Patent No. 7,527,787, entitled "Multivalent Immunoglobulin-based Bioreactive Assemblies." Claim 1 from the patent reads: 1. A hexameric stably tethered structure comprising an IgG antibody attached to two AD2 moieties of SEQ ID NO: 4…
-
By Kevin E. Noonan — Last Friday, the Biotechnology Industry Organization (BIO) presented its members-only 2009 Spring IP Policy Briefing to member companies, particularly directed to member law firms. The presentation was moderated by Lila Feisee, BIO's Managing Director, Intellectual Property. The briefing included discussions on Membership Benefits, U.S. court cases, biosimilars and patent…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Yeda Research and Development Co., Ltd., v. Doll1:09-cv-00820; filed May 4, 2009 in the District Court of the District of Columbia Review…
-
May 18-21, 2009 – BIO International Convention (Biotechnology Industry Organization) – Atlanta, GA May 20, 2009 – Tafas v. Doll — Dissecting the Decision and Preparing for Resurgence of USPTO Rules Limiting Patent Claims*** (American Conference Institute) – 1:00-2:30 PM (EST) June 16-17, 2009 – Biotech Patenting (C5) – Munich, Germany June 19, 2009 –…
-
American Conference Institute (ACI) will be holding the next session of its FDA Boot Camp conference on July 21-22, 2009 in Chicago, IL. The conference will allow attendees to: • Master the basics of the approval processes for drugs, biologics, and devices, including in-depth discussion of the application, pre-approval, and post-approval requirements;• Comprehend the structure…
-
By Christopher P. Singer — As we previously reported by Patent Docs, the U.S. Patent and Trademark Office began a Patent Prosecution Highway (PPH) Pilot Program with the German Patent and Trademark Office (DPMA) on April 27, 2009 which will last for two years. The USPTO issued another press release on April 20, 2009,…
-
By Mark Chael — On April 29, 2009, ImmunoCellular Therapeutics, Ltd. announced that the U.S. Patent and Trademark Office issued Patent No. 7,498,129, which relates to the company's monoclonal antibody platform. The '129 patent is entitled "Myeloma Cell and Ovarian Cancer Cell Surface Glycoproteins, Antibodies Thereto, and Uses Thereof," and according to ImmunoCellular, is…
-
By Kevin E. Noonan — U.S. Trade Representative Ron Kirk issued a "Special 301 Report" on April 30. This report, on the state of intellectual property rights worldwide, identifies twelve countries on a "priority watch list" and another 33 on a "watch list," all relating to deficiencies in intellectual property protection in these countries. …
-
By Mark Chael — On April 29, 2009, Raptor Pharmaceuticals Corp. announced that the U.S. Patent and Trademark Office recently issued Notices of Allowance for two of its pending patent applications related to methods of delivering drugs to the brain. The Notices were issued for U.S. Patent Application Nos. 10/812,849 and 11/202,566. The published…
-
By Suresh Pillai — Novartis Denied Jury Trial in Famvir® Suit Last week, the U.S. District Court for the District of New Jersey denied Novartis Pharmaceutical Corp.'s request for a jury trial in its suit against Roxane Laboratories Inc. In the lawsuit, filed in July 2008 (see "Court Report," May 18, 2008), Norvartis alleges…
Patent Docs 